#efruxifermin
LightNews LightNews
tsubodaisuki.bsky.social
MASH代償性肝硬変に対するefruxiferminの有用性（解説：相澤 良夫 氏）－1974｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTFA4SVVJVkJaNEpyb1puQTZKc1FmcmhyNDl5OGpOc2UtOWx3SHc0QmU2a3l4YU5Ca1Ryd3JOYk9OM2RyN1lwMkdQMVBHTUxpS1M3NlJzbGNKb2wwOGZS?oc=5
June 19, 2025 at 8:09 AM
tsubodaisuki.bsky.social
線維化を伴うMASH、efruxiferminが線維化を改善／Lancet｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiX0FVX3lxTE42cmZNZXI1LXpSVURtMEduRV9Ia2pjSHFyVDUyUVllU1cwRDd2a0k0NUFFT3cyODViaGRiaWJjVTNaV1U2ZmhwZEdCVlFyRDZ3c1lpUmI2WkZKSzFnTHdn?oc=5
August 29, 2025 at 5:09 AM
natrevgastrohep.nature.com
OCTOBER ISSUE | RESEARCH HIGHLIGHT "AI-assisted colonoscopy and risk of endoscopist deskilling"

www.nature.com/articles/s41...

#Gastrosky
Research highlights: 1. Vaccine for pancreatic and colorectal cancer: phase I AMPLIFY-201 trial 2. Changes in cholera burden across Africa 3. Positive longer-term results for efruxifermin in MASH 4. AI-assisted colonoscopy and risk of endoscopist deskilling MASH, metabolic dysfunction-associated steatohepatitis AI, artificial intelligence
September 25, 2025 at 7:59 AM
nixassedes.bsky.social
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
www.sciencedirect.com/science/arti...
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
In phase 2 studies, efruxifermin, an Fc–FGF21 analog, significantly reduced steatohepatitis and fibrosis in patients with non-alcoholic steatohepatiti…
www.sciencedirect.com
December 20, 2024 at 9:48 PM
natrevgastrohep.nature.com
ICYMI: New online! Positive longer-term results for efruxifermin in MASH
Positive longer-term results for efruxifermin in MASH
Nature Reviews Gastroenterology & Hepatology, Published online: 05 September 2025; doi:10.1038/s41575-025-01121-4Positive longer-term results for efruxifermin in MASH
www.nature.com
September 6, 2025 at 3:32 PM
nejm.org
In patients with compensated cirrhosis from metabolic dysfunction–associated steatohepatitis, efruxifermin did not significantly reduce fibrosis at 36 weeks. Full SYMMETRY trial results: nej.md/4kru98f

@easlnews.bsky.social #MedSky #EASLCongress
Bar charts of the percentage of patients with a reduction in fibrosis without a worsening of metabolic dysfunction–associated steatohepatitis (MASH) at week 36 (primary outcome) (Panel A) and at week 96 (a secondary outcome) (Panel B).
May 9, 2025 at 10:20 AM
tsubodaisuki.bsky.social
MASH代償性肝硬変に対するefruxiferminの有用性（解説：相澤 良夫 氏）－1974｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTFA4SVVJVkJaNEpyb1puQTZKc1FmcmhyNDl5OGpOc2UtOWx3SHc0QmU2a3l4YU5Ca1Ryd3JOYk9OM2RyN1lwMkdQMVBHTUxpS1M3NlJzbGNKb2wwOGZS?oc=5
June 19, 2025 at 9:09 AM
rcatanho.bsky.social
Efruxifermin revierte la fibrosis, resuelve la esteatohepatitis, reduce los marcadores de daño hepático y mejora la sensibilidad a la insulina y perfil de lipoproteínas en pacientes con cirrosis compensada por esteatohepatitis asociada a la disfunción metabólica firstwordpharma.com/story/5930434
FirstWord
firstwordpharma.com
January 27, 2025 at 4:26 PM
livermd.bsky.social
Great news for persons w/ #MASH cirrhosis in this ph2b study of #efruxifermin
Thoughts:
🤞it is a fair statement that longer rx may yield better results but that remains to be proven
the authors are to be 👏 for presenting ITT data. MASH studies needs to move away from “completer” analyses
#liversky
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SY...
Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of...
www.globenewswire.com
January 28, 2025 at 4:00 AM
tsubodaisuki.bsky.social
線維化を伴うMASH、efruxiferminが線維化を改善／Lancet｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiX0FVX3lxTE42cmZNZXI1LXpSVURtMEduRV9Ia2pjSHFyVDUyUVllU1cwRDd2a0k0NUFFT3cyODViaGRiaWJjVTNaV1U2ZmhwZEdCVlFyRDZ3c1lpUmI2WkZKSzFnTHdn?oc=5
August 29, 2025 at 6:09 AM
tsubodaisuki.bsky.social
MASH代償性肝硬変に対するefruxiferminの有用性（解説：相澤 良夫 氏）－1974｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTFA4SVVJVkJaNEpyb1puQTZKc1FmcmhyNDl5OGpOc2UtOWx3SHc0QmU2a3l4YU5Ca1Ryd3JOYk9OM2RyN1lwMkdQMVBHTUxpS1M3NlJzbGNKb2wwOGZS?oc=5
June 19, 2025 at 12:09 PM
tsubodaisuki.bsky.social
MASH代償性肝硬変に対するefruxiferminの有用性（解説：相澤 良夫 氏）－1974｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTFA4SVVJVkJaNEpyb1puQTZKc1FmcmhyNDl5OGpOc2UtOWx3SHc0QmU2a3l4YU5Ca1Ryd3JOYk9OM2RyN1lwMkdQMVBHTUxpS1M3NlJzbGNKb2wwOGZS?oc=5
June 19, 2025 at 11:09 AM
tsubodaisuki.bsky.social
MASH代償性肝硬変に対するefruxiferminの有用性（解説：相澤 良夫 氏）－1974｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiXEFVX3lxTFA4SVVJVkJaNEpyb1puQTZKc1FmcmhyNDl5OGpOc2UtOWx3SHc0QmU2a3l4YU5Ca1Ryd3JOYk9OM2RyN1lwMkdQMVBHTUxpS1M3NlJzbGNKb2wwOGZS?oc=5
June 19, 2025 at 2:09 PM
endpts.com
Akero's efruxifermin showed benefit on fibrosis reduction, the company said on Monday. $AKRO shares jumped 98% premarket.
Updated: Akero redeems its failure in severe MASH with longer-term data
Akero Therapeutics claimed a win in severe MASH on Monday morning, as the company’s candidate efruxifermin showed a 24% benefit on fibrosis reduction over placebo in a crucial mid-stage trial.
endpts.com
January 27, 2025 at 8:30 PM
tsubodaisuki.bsky.social
MASHによる代償性肝硬変、efruxiferminは線維化を改善せず／NEJM｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiX0FVX3lxTE1pMUJBY2NqWXZtVl9IVDJoNWVST1RpeDhJVTBUN1o4WGh0bjNRSGZBTk5PaGRjSTUzU25XZ2s5RHFjY1lfTVFEbG5RLURSaGcwVjVhMUUyLS1qVFJNdUJ3?oc=5
May 22, 2025 at 9:09 PM
hepmag.bsky.social
Efruxifermin Improves Liver Cirrhosis in People With #MASH www.hepmag.com/article/efru...
Efruxifermin Improves Liver Cirrhosis in People With MASH
The fibroblast growth factor analog reduced liver scarring in about a third of people with fatty liver disease and cirrhosis.
www.hepmag.com
February 1, 2025 at 3:06 PM
nejm.org
In patients with compensated cirrhosis from metabolic dysfunction–associated steatohepatitis, efruxifermin did not significantly reduce fibrosis at 36 weeks. Full SYMMETRY trial results and Research Summary: nej.md/4kru98f

#MedSky #EndoSky
The New England Journal of Medicine Efruxifermin in Compensated Liver Cirrhosis Caused by MASH A Research Summary based on Noureddin M et al. | 10.1056/NEJMoa2502242 | Published on May 9, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
July 1, 2025 at 4:04 PM
notreload.bsky.social
$NVO -1%, $AKRO +17.8%, $VKTX +3.9% ... [Novo Nordisk has agreed to acquire clinical-stage Akero Therapeutics for up to $5.2 billion to integrate efruxifermin (EFX), a promising late-stage treatment for MASH, complementing Novo Nordisk's leadership in cardiometabolic disease.]
Novo Nordisk Acquires Akero for MASH Treatment Expansion
Novo Nordisk has agreed to acquire clinical-stage Akero Therapeutics for up to $5.2 billion to integrate efruxifermin (EFX), a promising late-stage treatment for MASH, complementing Novo Nordisk's lea...
notreload.xyz
October 9, 2025 at 12:30 PM
tsubodaisuki.bsky.social
MASHによる代償性肝硬変、efruxiferminは線維化を改善せず／NEJM｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiX0FVX3lxTE1pMUJBY2NqWXZtVl9IVDJoNWVST1RpeDhJVTBUN1o4WGh0bjNRSGZBTk5PaGRjSTUzU25XZ2s5RHFjY1lfTVFEbG5RLURSaGcwVjVhMUUyLS1qVFJNdUJ3?oc=5
May 22, 2025 at 10:09 PM
mattiasmandorfer.bsky.social
📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)

👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3

🖇️ for explanation: authors.elsevier.com/sd/article/S...
October 3, 2025 at 7:06 AM
baladocritique.bsky.social
"Efruxifermin in Compensated Liver Cirrhosis Caused by MASH."
Publié ce jour dans le @nejm.org.
#MedSky #GastroSky #LiverSky
www.nejm.org/doi/full/10....
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH | NEJM
In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analo...
www.nejm.org
June 26, 2025 at 11:25 AM
tsubodaisuki.bsky.social
MASHによる代償性肝硬変、efruxiferminは線維化を改善せず／NEJM｜CareNet.com - CareNet.com
news.google.com/rss/articles/CBMiX0FVX3lxTE1pMUJBY2NqWXZtVl9IVDJoNWVST1RpeDhJVTBUN1o4WGh0bjNRSGZBTk5PaGRjSTUzU25XZ2s5RHFjY1lfTVFEbG5RLURSaGcwVjVhMUUyLS1qVFJNdUJ3?oc=5
May 22, 2025 at 11:09 PM
natrevgastrohep.nature.com
OCTOBER ISSUE | RESEARCH HIGHLIGHT "Positive longer-term results for efruxifermin in MASH"

www.nature.com/articles/s41...

#Liversky #Medsky
Research highlights: 1. Vaccine for pancreatic and colorectal cancer: phase I AMPLIFY-201 trial 2. Changes in cholera burden across Africa 3. Positive longer-term results for efruxifermin in MASH 4. AI-assisted colonoscopy and risk of endoscopist deskilling MASH, metabolic dysfunction-associated steatohepatitis AI, artificial intelligence
September 25, 2025 at 7:59 AM
oninvest.bsky.social
💊 #NVO will acquire #AkeroTherapeutics for up to $5.2B, paying $54/share in cash plus $6/share if its liver drug efruxifermin wins U.S. approval by 2031. It’s Novo Nordisk’s first big move under new CEO Mike Doustdar to expand beyond obesity and diabetes en.oninvest.com/article/live...
en.oninvest.com
October 10, 2025 at 3:38 AM
newsen.bsky.social
Potential Legal Trouble Looms for Akero Therapeutics as Berger Montague Launches Investigation#USA#San_Francisco#Berger_Montague#Akero_Therapeutics#Efruxifermin
Potential Legal Trouble Looms for Akero Therapeutics as Berger Montague Launches Investigation
Berger Montague PC is probing Akero Therapeutics, Inc. regarding potential breaches of fiduciary duties and violations of securities laws, impacting shareholders and future mergers.
third-news.com
November 4, 2025 at 9:48 PM